$2,700.00
A stable CHO cell line overexpressing hERG potassium channels for studying Kv11.1 pharmacology and safety screening.
ION Assurance – We guarantee product quality. If you’re unsatisfied with your order, send us an email at support@ionbiosciences.com. We’ll promptly address your concern and replace, credit, or refund your items according to our ION Assurance terms and conditions.
Size: 2 x 10⁶M cells
Cells/vial: 2 x 10⁶
Mycoplasma test: Pass
Species: Human
Guaranteed performance: > 10 passages
Our CHO-K1 Kv11.1 (hERG) Recombinant Cell Line is a high-performance, stably expressing cell for cardiotoxicity screening and hERG drug discovery. Validated using fluorescence-based assays, like Brilliant Thallium Assay, and Automated Patch Clamp (APC) platforms, including the SyncroPatch 384, this essential cell line provides complete coverage for your hERG screening needs.
hERG channels (Kv11.1, KCNH2) are essential for cardiac repolarization, and their inhibition is a primary concern in drug safety assessment due to the risk of long QT syndrome and potential fatal arrhythmias. Given the FDA’s stringent CiPA (Comprehensive in Vitro Proarrhythmia Assay) guidelines, rigorous hERG screening is a critical step in drug development to identify off-target cardiac effects.
Using this cell line in high-throughput electrophysiology and fluorescence assays allows for precise IC₅₀ determinations of known hERG inhibitors, ensuring alignment with regulatory expectations and literature benchmarks. Recent pharmacological validation with Bepridil, Diltiazem, Ranolazine, and Verapamil confirmed its reliability in predicting hERG-related drug interactions across multiple assay formats and temperature conditions.
Ensure your cardiac safety and ion channel screening workflows are backed by the highest-quality recombinant hERG cell line.
Our hERG-expressing CHO K1 cells were also validated with automated electrophysiology using the SyncroPatch 384 from Nanion Technologies, highlighting ION’s CHO K1 hERG cell line is an excellent tool for cardiac safety profiling.
